Improved vision-related function after ranibizumab vs photodynamic therapy: A randomized clinical trial

Neil M Bressler, Tom S. Chang, Jennifer T. Fine, Chantal M. Dolan, James Ward

Research output: Contribution to journalArticle

Abstract

Objective: To compare patient-reported visual function in those with neovascular age-related macular degeneration treated with ranibizumab or verteporfin photodynamic therapy (PDT). Design: Multicenter, double-masked, phase 3 trial (ANCHOR). Participants were randomized in a 1:1:1 ratio to receive 0.3 or 0.5mgof intravitreal ranibizumab plus sham verteporfin or sham injections plus active verteporfin monthly. The National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was administered at baseline and 1, 2, 3, 6, 9, 12, 18, and 24 months. Main Outcome Measure: Mean change from baseline in NEI VFQ-25 scores at 12 months. Results: At 12 months, patients treated with ranibizumab (0.3 mg [n=137] or 0.5 mg [n=139]) had mean improvements in NEI VFQ-25 composite scores of 5.9 (95% confidence interval [CI], 3.6 to 8.3) and 8.1 (95% CI, 5.3 to 10.8) points, respectively; patients treated with PDT(n=142) had a mean improvement of 2.2 points (95% CI, -0.3 to 4.7; vs 0.5 mg of ranibizumab, P

Original languageEnglish (US)
Pages (from-to)13-21
Number of pages9
JournalArchives of Ophthalmology
Volume127
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

National Eye Institute (U.S.)
Photochemotherapy
Randomized Controlled Trials
Confidence Intervals
Macular Degeneration
Outcome Assessment (Health Care)
Injections
Ranibizumab
Surveys and Questionnaires
verteporfin

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Improved vision-related function after ranibizumab vs photodynamic therapy : A randomized clinical trial. / Bressler, Neil M; Chang, Tom S.; Fine, Jennifer T.; Dolan, Chantal M.; Ward, James.

In: Archives of Ophthalmology, Vol. 127, No. 1, 01.2009, p. 13-21.

Research output: Contribution to journalArticle

Bressler, Neil M ; Chang, Tom S. ; Fine, Jennifer T. ; Dolan, Chantal M. ; Ward, James. / Improved vision-related function after ranibizumab vs photodynamic therapy : A randomized clinical trial. In: Archives of Ophthalmology. 2009 ; Vol. 127, No. 1. pp. 13-21.
@article{16147056edcc43579c6223ad5bfd871a,
title = "Improved vision-related function after ranibizumab vs photodynamic therapy: A randomized clinical trial",
abstract = "Objective: To compare patient-reported visual function in those with neovascular age-related macular degeneration treated with ranibizumab or verteporfin photodynamic therapy (PDT). Design: Multicenter, double-masked, phase 3 trial (ANCHOR). Participants were randomized in a 1:1:1 ratio to receive 0.3 or 0.5mgof intravitreal ranibizumab plus sham verteporfin or sham injections plus active verteporfin monthly. The National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was administered at baseline and 1, 2, 3, 6, 9, 12, 18, and 24 months. Main Outcome Measure: Mean change from baseline in NEI VFQ-25 scores at 12 months. Results: At 12 months, patients treated with ranibizumab (0.3 mg [n=137] or 0.5 mg [n=139]) had mean improvements in NEI VFQ-25 composite scores of 5.9 (95{\%} confidence interval [CI], 3.6 to 8.3) and 8.1 (95{\%} CI, 5.3 to 10.8) points, respectively; patients treated with PDT(n=142) had a mean improvement of 2.2 points (95{\%} CI, -0.3 to 4.7; vs 0.5 mg of ranibizumab, P",
author = "Bressler, {Neil M} and Chang, {Tom S.} and Fine, {Jennifer T.} and Dolan, {Chantal M.} and James Ward",
year = "2009",
month = "1",
doi = "10.1001/archophthalmol.2008.562",
language = "English (US)",
volume = "127",
pages = "13--21",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Improved vision-related function after ranibizumab vs photodynamic therapy

T2 - A randomized clinical trial

AU - Bressler, Neil M

AU - Chang, Tom S.

AU - Fine, Jennifer T.

AU - Dolan, Chantal M.

AU - Ward, James

PY - 2009/1

Y1 - 2009/1

N2 - Objective: To compare patient-reported visual function in those with neovascular age-related macular degeneration treated with ranibizumab or verteporfin photodynamic therapy (PDT). Design: Multicenter, double-masked, phase 3 trial (ANCHOR). Participants were randomized in a 1:1:1 ratio to receive 0.3 or 0.5mgof intravitreal ranibizumab plus sham verteporfin or sham injections plus active verteporfin monthly. The National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was administered at baseline and 1, 2, 3, 6, 9, 12, 18, and 24 months. Main Outcome Measure: Mean change from baseline in NEI VFQ-25 scores at 12 months. Results: At 12 months, patients treated with ranibizumab (0.3 mg [n=137] or 0.5 mg [n=139]) had mean improvements in NEI VFQ-25 composite scores of 5.9 (95% confidence interval [CI], 3.6 to 8.3) and 8.1 (95% CI, 5.3 to 10.8) points, respectively; patients treated with PDT(n=142) had a mean improvement of 2.2 points (95% CI, -0.3 to 4.7; vs 0.5 mg of ranibizumab, P

AB - Objective: To compare patient-reported visual function in those with neovascular age-related macular degeneration treated with ranibizumab or verteporfin photodynamic therapy (PDT). Design: Multicenter, double-masked, phase 3 trial (ANCHOR). Participants were randomized in a 1:1:1 ratio to receive 0.3 or 0.5mgof intravitreal ranibizumab plus sham verteporfin or sham injections plus active verteporfin monthly. The National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was administered at baseline and 1, 2, 3, 6, 9, 12, 18, and 24 months. Main Outcome Measure: Mean change from baseline in NEI VFQ-25 scores at 12 months. Results: At 12 months, patients treated with ranibizumab (0.3 mg [n=137] or 0.5 mg [n=139]) had mean improvements in NEI VFQ-25 composite scores of 5.9 (95% confidence interval [CI], 3.6 to 8.3) and 8.1 (95% CI, 5.3 to 10.8) points, respectively; patients treated with PDT(n=142) had a mean improvement of 2.2 points (95% CI, -0.3 to 4.7; vs 0.5 mg of ranibizumab, P

UR - http://www.scopus.com/inward/record.url?scp=58449085584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449085584&partnerID=8YFLogxK

U2 - 10.1001/archophthalmol.2008.562

DO - 10.1001/archophthalmol.2008.562

M3 - Article

C2 - 19139332

AN - SCOPUS:58449085584

VL - 127

SP - 13

EP - 21

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 1

ER -